Vrillon, Agathe
Bousiges, Olivier
Götze, Karl
Demuynck, Catherine
Muller, Candice
Ravier, Alix
Schorr, Benoît
Philippi, Nathalie
Hourregue, Claire
Cognat, Emmanuel
Dumurgier, Julien
Lilamand, Matthieu
Cretin, Benjamin
Blanc, Frédéric
Paquet, Claire
Funding for this research was provided by:
A2MCL
Article History
Received: 12 March 2024
Accepted: 12 June 2024
First Online: 3 July 2024
Declarations
:
: All patients or their legal relatives gave written informed consent to their participation in the study. For Paris cohort, the collection and analysis of samples were approved by the local ethic committee of Bichat University, Paris, France (CEERB GHU Nord n°10–037). For Strasbourg cohort, this study was part of the larger cohort study AlphaLewyMA (, registered June 11, 2013), approved by the ethics committee of East France (IV). All procedures were in accordance with the Declaration of Helsinki.
: Not applicable.
: F.B. was the national coordinator for France for the Eisai Delphia (E2027), Axovant Headway-DLB and Roche Graduate therapeutic trials; he had received honoraria from Roche, Eisai and Biogen for oral presentations, and from Eisai for a board. C.P. is a member of the International Advisory Boards of Lilly; is a consultant for Fujiribio, Alzhois, Neuroimmune, Ads Neuroscience, Roche, AgenT and Gilead; and is involved as an investigator in several clinical trials for Roche, Esai, Lilly, Biogen, Astrazeneca, Lundbeck, and Neuroimmune. All other authors report no conflicts of interest.